Vascular	0	8	B-Multi-tissue_structure
proliferation	9	22	O
and	23	26	O
enhanced	27	35	O
expression	36	46	O
of	47	49	O
endothelial	50	61	B-Gene_or_gene_product
nitric	62	68	I-Gene_or_gene_product
oxide	69	74	I-Gene_or_gene_product
synthase	75	83	I-Gene_or_gene_product
in	84	86	O
human	87	92	B-Organism
peritoneum	93	103	B-Multi-tissue_structure
exposed	104	111	O
to	112	114	O
long	115	119	O
-	119	120	O
term	120	124	O
peritoneal	125	135	O
dialysis	136	144	O
.	144	145	O

Long	147	151	O
-	151	152	O
term	152	156	O
peritoneal	157	167	O
dialysis	168	176	O
(	177	178	O
PD	178	180	O
)	180	181	O
is	182	184	O
associated	185	195	O
with	196	200	O
alterations	201	212	O
in	213	215	O
peritoneal	216	226	O
permeability	227	239	O
and	240	243	O
loss	244	248	O
of	249	251	O
ultrafiltration	252	267	O
.	267	268	O

These	269	274	O
changes	275	282	O
originate	283	292	O
from	293	297	O
increased	298	307	O
peritoneal	308	318	B-Immaterial_anatomical_entity
surface	319	326	I-Immaterial_anatomical_entity
area	327	331	I-Immaterial_anatomical_entity
,	331	332	O
but	333	336	O
the	337	340	O
morphologic	341	352	O
and	353	356	O
molecular	357	366	O
mechanisms	367	377	O
involved	378	386	O
remain	387	393	O
unknown	394	401	O
.	401	402	O

The	403	406	O
hypothesis	407	417	O
that	418	422	O
modifications	423	436	O
of	437	439	O
activity	440	448	O
and	449	452	O
/	452	453	O
or	453	455	O
expression	456	466	O
of	467	469	O
nitric	470	476	B-Gene_or_gene_product
oxide	477	482	I-Gene_or_gene_product
synthase	483	491	I-Gene_or_gene_product
(	492	493	O
NOS	493	496	B-Gene_or_gene_product
)	496	497	O
isozymes	498	506	O
might	507	512	O
play	513	517	O
a	518	519	O
role	520	524	O
in	525	527	O
these	528	533	O
modifications	534	547	O
,	547	548	O
via	549	552	O
enhanced	553	561	O
local	562	567	O
production	568	578	O
of	579	581	O
nitric	582	588	B-Drug_or_compound
oxide	589	594	I-Drug_or_compound
,	594	595	O
was	596	599	O
tested	600	606	O
in	607	609	O
this	610	614	O
study	615	620	O
.	620	621	O

NOS	622	625	B-Gene_or_gene_product
activities	626	636	O
were	637	641	O
measured	642	650	O
by	651	653	O
the	654	657	O
L	658	659	O
-	659	660	O
citrulline	660	670	O
assay	671	676	O
in	677	679	O
peritoneal	680	690	O
biopsies	691	699	O
from	700	704	O
seven	705	710	O
control	711	718	O
subjects	719	727	O
,	727	728	O
eight	729	734	O
uremic	735	741	O
patients	742	750	B-Organism
immediately	751	762	O
before	763	769	O
the	770	773	O
onset	774	779	O
of	780	782	O
PD	783	785	O
,	785	786	O
and	787	790	O
13	791	793	O
uremic	794	800	O
patients	801	809	B-Organism
on	810	812	O
short	813	818	O
-	818	819	O
term	819	823	O
(	824	825	O
less	826	830	O
than	831	835	O
18	836	838	O
mo	839	841	O
,	841	842	O
n	843	844	O
=	845	846	O
6	847	848	O
)	848	849	O
or	850	852	O
long	853	857	O
-	857	858	O
term	858	862	O
(	862	863	O
greater	864	871	O
than	872	876	O
18	877	879	O
mo	880	882	O
,	882	883	O
n	884	885	O
=	886	887	O
7	888	889	O
)	889	890	O
PD	891	893	O
.	893	894	O

Peritoneal	895	905	O
NOS	906	909	B-Gene_or_gene_product
activity	910	918	O
is	919	921	O
increased	922	931	O
fivefold	932	940	O
in	941	943	O
long	944	948	O
-	948	949	O
term	949	953	O
PD	954	956	O
patients	957	965	B-Organism
compared	966	974	O
with	975	979	O
control	980	987	O
subjects	988	996	O
.	996	997	O

In	998	1000	O
uremic	1001	1007	O
patients	1008	1016	B-Organism
,	1016	1017	O
NOS	1018	1021	B-Gene_or_gene_product
activity	1022	1030	O
is	1031	1033	O
positively	1034	1044	O
correlated	1045	1055	O
with	1056	1060	O
the	1061	1064	O
duration	1065	1073	O
of	1074	1076	O
PD	1077	1079	O
.	1079	1080	O

Increased	1081	1090	O
NOS	1091	1094	B-Gene_or_gene_product
activity	1095	1103	O
is	1104	1106	O
mediated	1107	1115	O
solely	1116	1122	O
by	1123	1125	O
Ca	1126	1128	O
(	1128	1129	O
2	1129	1130	O
+	1130	1131	O
)	1131	1132	O
-	1132	1133	O
dependent	1133	1142	O
NOS	1143	1146	B-Gene_or_gene_product
and	1147	1150	O
,	1150	1151	O
as	1152	1154	O
shown	1155	1160	O
by	1161	1163	O
immunoblotting	1164	1178	O
,	1178	1179	O
an	1180	1182	O
upregulation	1183	1195	O
of	1196	1198	O
endothelial	1199	1210	B-Gene_or_gene_product
NOS	1211	1214	I-Gene_or_gene_product
.	1214	1215	O

The	1216	1219	O
biologic	1220	1228	O
relevance	1229	1238	O
of	1239	1241	O
increased	1242	1251	O
NOS	1252	1255	B-Gene_or_gene_product
in	1256	1258	O
long	1259	1263	O
-	1263	1264	O
term	1264	1268	O
PD	1269	1271	O
was	1272	1275	O
demonstrated	1276	1288	O
by	1289	1291	O
enhanced	1292	1300	O
nitrotyrosine	1301	1314	B-Drug_or_compound
immunoreactivity	1315	1331	O
and	1332	1335	O
a	1336	1337	O
significant	1338	1349	O
increase	1350	1358	O
in	1359	1361	O
vascular	1362	1370	B-Multi-tissue_structure
density	1371	1378	O
and	1379	1382	O
endothelial	1383	1394	B-Tissue
area	1395	1399	I-Tissue
in	1400	1402	O
the	1403	1406	O
peritoneum	1407	1417	B-Multi-tissue_structure
.	1417	1418	O

Immunoblotting	1419	1433	O
and	1434	1437	O
immunostaining	1438	1452	O
studies	1453	1460	O
demonstrated	1461	1473	O
an	1474	1476	O
upregulation	1477	1489	O
of	1490	1492	O
vascular	1493	1501	B-Gene_or_gene_product
endothelial	1502	1513	I-Gene_or_gene_product
growth	1514	1520	I-Gene_or_gene_product
factor	1521	1527	I-Gene_or_gene_product
(	1528	1529	O
VEGF	1529	1533	B-Gene_or_gene_product
)	1533	1534	O
mostly	1535	1541	O
along	1542	1547	O
the	1548	1551	O
endothelium	1552	1563	B-Tissue
lining	1564	1570	O
peritoneal	1571	1581	B-Multi-tissue_structure
blood	1582	1587	I-Multi-tissue_structure
vessels	1588	1595	I-Multi-tissue_structure
in	1596	1598	O
long	1599	1603	O
-	1603	1604	O
term	1604	1608	O
PD	1609	1611	O
patients	1612	1620	B-Organism
.	1620	1621	O

In	1622	1624	O
the	1625	1628	O
latter	1629	1635	O
,	1635	1636	O
VEGF	1637	1641	B-Gene_or_gene_product
colocalized	1642	1653	O
with	1654	1658	O
the	1659	1662	O
advanced	1663	1671	O
glycation	1672	1681	O
end	1682	1685	O
product	1686	1693	O
pentosidine	1694	1705	B-Drug_or_compound
deposits	1706	1714	O
.	1714	1715	O

These	1716	1721	O
data	1722	1726	O
provide	1727	1734	O
a	1735	1736	O
morphologic	1737	1748	O
(	1749	1750	O
angiogenesis	1750	1762	O
and	1763	1766	O
increased	1767	1776	O
endothelial	1777	1788	B-Tissue
area	1789	1793	I-Tissue
)	1793	1794	O
and	1795	1798	O
molecular	1799	1808	O
(	1809	1810	O
enhanced	1810	1818	O
NOS	1819	1822	B-Gene_or_gene_product
activity	1823	1831	O
and	1832	1835	O
endothelial	1836	1847	B-Gene_or_gene_product
NOS	1848	1851	I-Gene_or_gene_product
upregulation	1852	1864	O
)	1864	1865	O
basis	1866	1871	O
for	1872	1875	O
explaining	1876	1886	O
the	1887	1890	O
permeability	1891	1903	O
changes	1904	1911	O
observed	1912	1920	O
in	1921	1923	O
long	1924	1928	O
-	1928	1929	O
term	1929	1933	O
PD	1934	1936	O
.	1936	1937	O

They	1938	1942	O
also	1943	1947	O
support	1948	1955	O
the	1956	1959	O
implication	1960	1971	O
of	1972	1974	O
local	1975	1980	O
advanced	1981	1989	O
glycation	1990	1999	O
end	2000	2003	O
product	2004	2011	O
deposits	2012	2020	O
and	2021	2024	O
liberation	2025	2035	O
of	2036	2038	O
VEGF	2039	2043	B-Gene_or_gene_product
in	2044	2046	O
that	2047	2051	O
process	2052	2059	O
.	2059	2060	O

